Mar 07, 2025 / 01:30PM GMT
Operator
Good morning, and welcome to Oncolytics Biotech's fourth-quarter and full-year 2024 conference call. (Operator Instructions) Please be advised that this call is being recorded at the company's request.
I would now like to turn the call over to Jon Patton, Director of Investor Relations and Communications. Please go ahead.
Jon Patton - Oncolytics Biotech Inc - Director of Investor Relations and Communication
Thank you, operator. Good morning, everyone, and welcome to Oncolytics fourth-quarter and full-year 2024 earnings call.
As a reminder, various remarks made during this call contain certain forward-looking statements relating to the company's business prospects and the development and commercialization of pelareorep, including statements regarding the company's mission, strategy, and milestones; the company's belief as to the potential and mechanism of action of pelareorep as a cancer therapeutic; our search for a new permanent CEO; our potential registrational opportunities for pelareorep and our plans and strategies related thereto;
Q4 2024 Oncolytics Biotech Inc Earnings Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |

30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot
